09.17.13
Abbott Park, Ill.-based Abbott Laboratories Inc. has earned CE mark approval for its Freestyle Optium Neo Blood Glucose and Ketone Monitoring System. The system provides visual glucose trend indicators and insulin logging, and is operated via a screen with icon indicators.
According to the World Health Organization, the prevalence of diabetes is increasing in the European region. Nearly 20 percent of women and men aged 25 years and older in Europe are living with diabetes, which makes diabetes one of the most prevalent chronic conditions.
The Freestyle Optium Neo system’s blood glucose trend indicators are designed to visually notify patients when they are experiencing hypo- or hyperglycemic trends (low or high blood glucose levels). An insulin dose feature allows healthcare professionals to program a patient’s insulin plan into the meter. Beginning from the physician’s recommendation in the dose guide, the meter is designed to allow patients to log actual insulin doses by tapping the arrows up or down. This feature is designed to enable patients and their healthcare professionals to review logged insulin doses along with glucose results.
“The FreeStyle Optium Neo system is our latest advance based on the innovative technology that is at the heart of both our Precision and Optium productsm,” said Heather Mason, senior vice president of the Diabetes Care division at Abbott. “It combines powerful features, ease-of-use and the ability to analyze important glucose trends in a single device. The device’s advanced design and technology enables the ability to track glucose trends and log insulin, which may help improve the patient’s daily diabetes management. This system is one more example of how Abbott is focused on meeting the needs of patients.”
The system is designed to be used with Freestyle Optium blood glucose and ketone test strips, which are currently available in Europe.
Abbott’s FreeStyle Optium Neo System will be available throughout the European Union in the coming weeks.
Abbott Diabetes Care is based in Alameda, Calif.
According to the World Health Organization, the prevalence of diabetes is increasing in the European region. Nearly 20 percent of women and men aged 25 years and older in Europe are living with diabetes, which makes diabetes one of the most prevalent chronic conditions.
The Freestyle Optium Neo system’s blood glucose trend indicators are designed to visually notify patients when they are experiencing hypo- or hyperglycemic trends (low or high blood glucose levels). An insulin dose feature allows healthcare professionals to program a patient’s insulin plan into the meter. Beginning from the physician’s recommendation in the dose guide, the meter is designed to allow patients to log actual insulin doses by tapping the arrows up or down. This feature is designed to enable patients and their healthcare professionals to review logged insulin doses along with glucose results.
“The FreeStyle Optium Neo system is our latest advance based on the innovative technology that is at the heart of both our Precision and Optium productsm,” said Heather Mason, senior vice president of the Diabetes Care division at Abbott. “It combines powerful features, ease-of-use and the ability to analyze important glucose trends in a single device. The device’s advanced design and technology enables the ability to track glucose trends and log insulin, which may help improve the patient’s daily diabetes management. This system is one more example of how Abbott is focused on meeting the needs of patients.”
The system is designed to be used with Freestyle Optium blood glucose and ketone test strips, which are currently available in Europe.
Abbott’s FreeStyle Optium Neo System will be available throughout the European Union in the coming weeks.
Abbott Diabetes Care is based in Alameda, Calif.